centrosomal protein 19Genealiases: C3orf34 · MOSPGF
Q-omics provides the consensus-scored CEP19 profile across patient tissues and cancer cell-line models. CEP19 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, CEP19 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, CEP19 RNA expression shows 20,588 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KICH, THCA, and KIRP as cancer lineages where CEP19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEP19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEP19 survival associations across molecular data types. CEP19 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEP19 RNA expression–survival associations across cancer types. High CEP19 expression shows unfavorable associations in KICH and LIHC, but favorable associations in HNSC, LUSC, ESCA and THYM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for CEP19 RNA expression.
This table summarizes CEP19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CEP19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEP19 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, HNSC, KIRP and STAD. The THCA box plot shows higher CEP19 RNA expression in normal versus tumor tissue (log2 FC = −1.089, t-test p < 0.001).
This table shows molecular features associated with CEP19 in patient tissues and cancer cell lines. In patient samples, CEP19 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CEP19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
